Molecular Residual Disease: From Detection to Trial-Ready Application

Molecular residual disease (MRD) assessment has evolved into an important tool in clinical oncology, enabling detection of residual cancer and assessment of relapse risk beyond the resolution of conventional imaging. MRD is increasingly informing clinical decision-making, offering deeper insight into disease persistence and treatment response.

As MRD technologies mature, the focus is shifting from detection alone to how these approaches can be applied reliably within clinical trials and oncology drug development. Advances in tumor-informed vs tumor agnostic approaches are improving the ability to detect low levels of disease while raising important questions around assay sensitivity, specificity, operational feasibility, and clinical applicability.

Join us for this webinar to explore key scientific and operational considerations in advancing MRD from a promising technology to a more trial-ready biomarker strategy. Topics will include assay design, performance tradeoffs, pre-analytical variables, and the evolving role of MRD in supporting patient stratification and earlier evaluation of treatment response in oncology development programs.

You’ll learn:

• How MRD is evolving from a research capability into a more clinically actionable development tool
• Key assay design and performance considerations that influence trial applicability
• The impact of sensitivity, specificity, and pre-analytical factors on MRD data interpretation
• Where tumor-informed vs tumor agnostic MRD approaches may support patient stratification and earlier treatment assessment